Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Elevai Labs, Inc. Common Stock (ELAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: ELAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Year Target Price $0
Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.94M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.95 - 839.86 | Updated Date 06/29/2025 |
52 Weeks Range 1.95 - 839.86 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.44 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.92% | Return on Equity (TTM) -95.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3351530 | Price to Sales(TTM) 2.34 |
Enterprise Value -3351530 | Price to Sales(TTM) 2.34 | ||
Enterprise Value to Revenue 2.59 | Enterprise Value to EBITDA - | Shares Outstanding 1375380 | Shares Floating 1259303 |
Shares Outstanding 1375380 | Shares Floating 1259303 | ||
Percent Insiders 0.49 | Percent Institutions 2.99 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Elevai Labs, Inc. Common Stock
Company Overview
History and Background
Elevai Labs, Inc. focuses on developing and commercializing physician-dispensed skincare products, particularly in the aesthetics market. They are relatively new on the public market.
Core Business Areas
- Topical Cosmetic Products: Development and sale of topical cosmetic products targeting skin aging and rejuvenation.
Leadership and Structure
Details on the specific leadership team and organizational structure can be found in the company's SEC filings and on their investor relations website. These typically include the CEO, CFO, and other key executive officers.
Top Products and Market Share
Key Offerings
- Elevai E-Series: A line of topical cosmetic products designed to improve skin texture, tone, and elasticity. Market share data specific to this product is often proprietary and not publicly available, competition includes ZO Skin Health, SkinCeuticals.
- Elevai Exosome: A line of exosomes based skincare products. Market share data specific to this product is often proprietary and not publicly available, competition includes Benev Company Inc, Kimera Labs.
Market Dynamics
Industry Overview
The aesthetics market, particularly physician-dispensed skincare, is a growing industry driven by increasing consumer interest in anti-aging and skin health. There is significant innovation in formulations and delivery methods.
Positioning
Elevai Labs aims to position itself as an innovator in the physician-dispensed aesthetics market, focusing on advanced formulations. Their competitive advantage is their exclusive license for exosome technology.
Total Addressable Market (TAM)
The global skincare market is estimated to be hundreds of billions of dollars, with a significant portion addressable by cosmeceutical products. Elevai Labs is positioned to capture a segment of this TAM with its specialized product offerings.
Upturn SWOT Analysis
Strengths
- Proprietary or patented technology
- Strong relationships with physicians and aesthetic clinics
- Focus on a high-growth market segment
- Innovative product offerings
Weaknesses
- Limited operating history as a public company
- Reliance on a small number of products
- Limited marketing and sales resources compared to larger competitors
- Dependence on distribution through physicians
Opportunities
- Expansion into new geographic markets
- Development of new product lines
- Partnerships with larger aesthetic companies
- Increasing consumer awareness of advanced skincare products
Threats
- Competition from established skincare brands
- Changing regulations in the aesthetics industry
- Economic downturn affecting consumer spending
- Patent infringement or challenges to their intellectual property
Competitors and Market Share
Key Competitors
- AGN
- SNTS
- ALGN
Competitive Landscape
Elevai Labs faces intense competition from established players with greater resources and brand recognition. They must differentiate themselves through innovation and effective marketing.
Growth Trajectory and Initiatives
Historical Growth: Growth depends on factors such as product acceptance, sales execution, and market conditions.
Future Projections: Future growth projections depend on analyst estimates, which would require access to a financial data API.
Recent Initiatives: Refer to company press releases and SEC filings for recent initiatives, such as product launches or partnerships.
Summary
Elevai Labs is a relatively new company focused on the growing aesthetics market with unique exosome and topical products. They show promise due to their exclusive licenses, but face strong competition and the need to effectively market their offerings. Their success will depend on their ability to build brand awareness, expand their distribution network, and successfully execute their growth strategy. Investors should closely monitor their financial performance and product adoption rates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Please consult with a qualified financial advisor before making any investment decisions. Market share data is approximate and based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elevai Labs, Inc. Common Stock
Exchange NASDAQ | Headquaters Newport Beach, CA, United States | ||
IPO Launch date 2023-11-21 | CEO, CFO, Secretary & Director Mr. Graydon Bensler C.F.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://pmgcholdings.com |
Full time employees 2 | Website https://pmgcholdings.com | ||
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.